Legend Biotech Jumps 42% On New Data -- Here's What Comes Next (NASDAQ:LEGN)
· seekingalpha.com
Buy Legend Biotech (LEGN): new Carvykti CARTITUDE-4 data show better survival and <1% Parkinsonism; upside at 3.0x EV/sales—read now.
My upside case here remains intact, and I’m still buy-rated on Legend Biotech Corporation ( LEGN ), since the story is increasingly showing us a pretty clear ...